HopeStage
Back to all studies
TerminatedNCT06011577

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

Medication studyAges 18–65United StatesDepression
The study in practice

Understand this study

Who could participate?

This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
Dothan and 35 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: August 17, 2023
Recruitment status
Terminated
Enrollment listed in the registry
27
Sponsor
Levomecor Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT06011577
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)

Recruitment & locations

Terminated

Dothan · Homewood · Anaheim

32 more locations
  • Lafayette
  • Newport Beach
  • Orange
  • Redlands
  • Sherman Oaks
  • Farmington
  • Brandon
  • Hialeah
  • Jacksonville
  • Miami
  • Okeechobee
  • Tampa
  • Springfield
  • Baltimore
  • Mankato
  • Toms River
  • Brooklyn
  • Cedarhurst
  • New York
  • Philadelphia
  • Franklin
  • Memphis
  • Austin
  • Bellaire
  • Friendswood
  • Houston
  • Wichita Falls
  • Clinton
  • Draper
  • Rutland
  • Charlottesville
  • Seattle

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Levomecor Inc.

Does this study involve medication?

Yes. The study involves medication, including REL-1017 and Placebo.

Who can participate?

This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies